352 related articles for article (PubMed ID: 18209734)
1. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.
Bennicelli J; Wright JF; Komaromy A; Jacobs JB; Hauck B; Zelenaia O; Mingozzi F; Hui D; Chung D; Rex TS; Wei Z; Qu G; Zhou S; Zeiss C; Arruda VR; Acland GM; Dell'Osso LF; High KA; Maguire AM; Bennett J
Mol Ther; 2008 Mar; 16(3):458-65. PubMed ID: 18209734
[TBL] [Abstract][Full Text] [Related]
2. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
[TBL] [Abstract][Full Text] [Related]
4. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
[TBL] [Abstract][Full Text] [Related]
5. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
[TBL] [Abstract][Full Text] [Related]
6. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection.
Jacobson SG; Acland GM; Aguirre GD; Aleman TS; Schwartz SB; Cideciyan AV; Zeiss CJ; Komaromy AM; Kaushal S; Roman AJ; Windsor EA; Sumaroka A; Pearce-Kelling SE; Conlon TJ; Chiodo VA; Boye SL; Flotte TR; Maguire AM; Bennett J; Hauswirth WW
Mol Ther; 2006 Jun; 13(6):1074-84. PubMed ID: 16644289
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
Li W; Kong F; Li X; Dai X; Liu X; Zheng Q; Wu R; Zhou X; Lü F; Chang B; Li Q; Hauswirth WW; Qu J; Pang JJ
Mol Vis; 2009; 15():267-75. PubMed ID: 19190735
[TBL] [Abstract][Full Text] [Related]
8. Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis.
Roman AJ; Boye SL; Aleman TS; Pang JJ; McDowell JH; Boye SE; Cideciyan AV; Jacobson SG; Hauswirth WW
Mol Vis; 2007 Sep; 13():1701-10. PubMed ID: 17960108
[TBL] [Abstract][Full Text] [Related]
9. In utero gene therapy rescues vision in a murine model of congenital blindness.
Dejneka NS; Surace EM; Aleman TS; Cideciyan AV; Lyubarsky A; Savchenko A; Redmond TM; Tang W; Wei Z; Rex TS; Glover E; Maguire AM; Pugh EN; Jacobson SG; Bennett J
Mol Ther; 2004 Feb; 9(2):182-8. PubMed ID: 14759802
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.
Amado D; Mingozzi F; Hui D; Bennicelli JL; Wei Z; Chen Y; Bote E; Grant RL; Golden JA; Narfstrom K; Syed NA; Orlin SE; High KA; Maguire AM; Bennett J
Sci Transl Med; 2010 Mar; 2(21):21ra16. PubMed ID: 20374996
[TBL] [Abstract][Full Text] [Related]
11. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA.
Jacobs JB; Dell'Osso LF; Wang ZI; Acland GM; Bennett J
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4685-92. PubMed ID: 19458334
[TBL] [Abstract][Full Text] [Related]
12. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.
Barker SE; Broderick CA; Robbie SJ; Duran Y; Natkunarajah M; Buch P; Balaggan KS; MacLaren RE; Bainbridge JW; Smith AJ; Ali RR
J Gene Med; 2009 Jun; 11(6):486-97. PubMed ID: 19340848
[TBL] [Abstract][Full Text] [Related]
13. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis.
Li X; Li W; Dai X; Kong F; Zheng Q; Zhou X; Lü F; Chang B; Rohrer B; Hauswirth WW; Qu J; Pang JJ
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):7-15. PubMed ID: 21169527
[TBL] [Abstract][Full Text] [Related]
15. AAV2 gene therapy readministration in three adults with congenital blindness.
Bennett J; Ashtari M; Wellman J; Marshall KA; Cyckowski LL; Chung DC; McCague S; Pierce EA; Chen Y; Bennicelli JL; Zhu X; Ying GS; Sun J; Wright JF; Auricchio A; Simonelli F; Shindler KS; Mingozzi F; High KA; Maguire AM
Sci Transl Med; 2012 Feb; 4(120):120ra15. PubMed ID: 22323828
[TBL] [Abstract][Full Text] [Related]
16. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Rolling F; Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Bull Mem Acad R Med Belg; 2006; 161(10-12):497-508; discussion 508-9. PubMed ID: 17503728
[TBL] [Abstract][Full Text] [Related]
17. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
[TBL] [Abstract][Full Text] [Related]
18. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
19. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.
Georgiadis A; Duran Y; Ribeiro J; Abelleira-Hervas L; Robbie SJ; Sünkel-Laing B; Fourali S; Gonzalez-Cordero A; Cristante E; Michaelides M; Bainbridge JW; Smith AJ; Ali RR
Gene Ther; 2016 Dec; 23(12):857-862. PubMed ID: 27653967
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis.
Pang JJ; Chang B; Kumar A; Nusinowitz S; Noorwez SM; Li J; Rani A; Foster TC; Chiodo VA; Doyle T; Li H; Malhotra R; Teusner JT; McDowell JH; Min SH; Li Q; Kaushal S; Hauswirth WW
Mol Ther; 2006 Mar; 13(3):565-72. PubMed ID: 16223604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
